PREPS and L-particles: a new approach to virus-like particle vaccines
- PMID: 12901580
- DOI: 10.1586/14760584.1.4.427
PREPS and L-particles: a new approach to virus-like particle vaccines
Abstract
Conventional virus-like particles are usually composed of a single structural protein which spontaneously assembles into particles. L-particles, a little-known type of virus-like particle, are produced as part of the natural infectious process of many, if not all, alpha-herpesviruses. L-particles lack the nucleocapsid present in the infectious virion but contain all of the virus envelope and tegument proteins. L-particles contain no virus DNA and are noninfectious, though they are biologically competent, since they are capable of delivering viral envelope and tegument proteins to cells. When cells are infected with herpes simplex virus Type 1 under conditions where viral DNA synthesis is blocked, previral DNA replication enveloped particles are produced. These are similar to L-particles, but differ slightly in protein composition. This article reviews the available data regarding these vaccine candidates and explores the wide-ranging potential applications, including vaccine candidates against infectious diseases and cancer, as well as a protein delivery vector.
Similar articles
-
The effect of herpes simplex virus type 1 L-particles on virus entry, replication, and the infectivity of naked herpesvirus DNA.Virology. 1997 Dec 22;239(2):378-88. doi: 10.1006/viro.1997.8893. Virology. 1997. PMID: 9434728
-
PREPs: herpes simplex virus type 1-specific particles produced by infected cells when viral DNA replication is blocked.J Virol. 1995 Aug;69(8):4924-32. doi: 10.1128/JVI.69.8.4924-4932.1995. J Virol. 1995. PMID: 7609061 Free PMC article.
-
Selection of particles and proteins for use as human cytomegalovirus subunit vaccines.Birth Defects Orig Artic Ser. 1984;20(1):305-24. Birth Defects Orig Artic Ser. 1984. PMID: 6329369 Review.
-
Improved titers for helper virus-free herpes simplex virus type 1 plasmid vectors by optimization of the packaging protocol and addition of noninfectious herpes simplex virus-related particles (previral DNA replication enveloped particles) to the packaging procedure.Hum Gene Ther. 1999 Aug 10;10(12):2005-11. doi: 10.1089/10430349950017365. Hum Gene Ther. 1999. PMID: 10466634
-
Virus-like particles: a new family of delivery systems.Expert Rev Vaccines. 2002 Jun;1(1):101-9. doi: 10.1586/14760584.1.1.101. Expert Rev Vaccines. 2002. PMID: 12908517 Review.
Cited by
-
Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine.Future Virol. 2012 Apr 1;7(4):371-378. doi: 10.2217/fvl.12.22. Future Virol. 2012. PMID: 22701511 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources